#Marengo Therapeutics #T Cell Immunology #UPenn

Marengo Therapeutics Partners with UPenn for Advanced T Cell Research

In a groundbreaking initiative, Marengo Therapeutics, Inc., a clinical-stage biotechnology firm, has announced a multi-year collaboration with the University of Pennsylvania’s Institute for Immunology and Immune Health. This partnership aims to advance innovative research in precision T cell immunology, focusing on oncology and autoimmune diseases.

Pioneering Precision Immunotherapy

Marengo Therapeutics is recognized for its pioneering work in reprogramming T cell repertoire and developing new therapeutic avenues in precision immunotherapy. The collaboration will specifically delve into the research of Marengo’s selective dual T cell agonists, enhancing their understanding of cancer treatment modalities, while simultaneously expanding their precision T cell depletion platform across various autoimmune conditions.

This partnership with Dr. E. John Wherry, a celebrated expert in T cell research and the director of the Penn Institute, promises to yield deeper insights into T cell mechanisms. Dr. Wherry’s expertise lies in characterizing T cell behaviors and exploring immune profiling to identify therapeutic targets crucial for combating different immunological diseases.

Targeting the T Cell Repertoire